Orange Book product · Brand (NDA)
RAPAFLO
SILODOSIN
At a glance
Oct 08, 2008
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 08, 2008
17 yr 11 mo ago
Today
Pharmaceutical detail
Active ingredient
SILODOSIN
Strength
8MG
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 022206
Product number
002
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2025SILODOSINGeneric (ANDA)
ANDA 210396 · TORRENT
- 2022SILODOSINGeneric (ANDA)
ANDA 204816 · ZYDUS PHARMS
- 2022SILODOSINGeneric (ANDA)
ANDA 209029 · PRINSTON INC
- 2022SILODOSINGeneric (ANDA)
ANDA 213230 · CREEKWOOD PHARMS
- 2020SILODOSINGeneric (ANDA)
ANDA 204793 · HETERO LABS LTD V
- 2019SILODOSINGeneric (ANDA)
ANDA 211731 · ALEMBIC
- 2018SILODOSINGeneric (ANDA)
ANDA 210626 · AUROBINDO PHARMA LTD
- 2018SILODOSINGeneric (ANDA)
ANDA 211060 · AJANTA PHARMA LTD
- 2018SILODOSINGeneric (ANDA)
ANDA 209745 · AMNEAL PHARMS CO
- 2018SILODOSINGeneric (ANDA)
ANDA 206541 · LUPIN
- 2018SILODOSINGeneric (ANDA)
ANDA 211166 · MACLEODS PHARMS LTD
- 2018SILODOSINGeneric (ANDA)
ANDA 210687 · MSN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
